• Mobile version
  • Follow us on Wechat
  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • App

Stories about GD winners of the 19th Chinese Patented Inventions Awards

Guangdong has topped the country in the number of invention patents granted over the past eight years. What’s more, 4 inventions from Guangdong companies received gold awards at the19th Chinese Outstanding Patented Inventions awards.

The winners covered a wide range of sectors such as new drugs, mobile payment and high-frequency spectrum technology.

The stories of three of these award winning Guangdong-based companies’ innovation follow below:

CCT’s microwave frequency conversion circuit and converter

 
 
China Communication Technology Co., Ltd, (CCT Technology), is a national high-tech enterprise based in Shenzhen, focusing on the R&D and application of high-frequency spectrum technology (including microwave, millimeter-wave and terahertz).

CCT’s patented tech uses symmetrical design of circuit units to reinforce the stability in signal output of microwave conversion.

Therefore, using just one satellite base station in Earth, the unit can receive data for TV, HD TV, and realize a two-way transmission of broadband data between Earth and satellites.

This technology is applicable to many satellite communication devices in cars, ships and aircraft; offering solutions for a variety of ocean-going, emergency, and military, uses.

The patented product is already being sold worldwide including European and American high-end markets.

In 2012, CCT received European and American orders amounting to 360 million Yuan; the following year, it signed deals worth 290 million USD with main satellite communications operators and satellite communications equipment sellers in Europe and America.

After acquiring G. TELECOMS, INC., the third biggest telecommunications operator in the Philippines, CCT has become the first Chinese satellite communications operator along the Belt and Road.


Nationz Technologies’ RCC application

 
 
Nationz Technologies Inc. is a leading provider of secure IC products and services in Internet ID authentication, security modules as well as personal digital security products and services.

The award-winning patent Is centered on Range Controlled Communication (RCC) and relevant systems. RCC is an innovative secure near-field communication technology, which integrates mobile payment, digital ID authentication, and more applications into a smart SIM card.

Compared to the NFC technology launched by foreign companies like Sony and Nokia, RCC is more easily integrated into a SIM card, leading to better end user experience and applicability.

The company pushed for their independently developed 2.45GHz RCC based mobile payment technology to become national standard from December 1st, 2017. It is already widely used for payment, transportation cards, campus IDs.

By the end of 2017, Nationz had sold above nine million RCC SIM cards and 400,000 card readers. The product had been launched in cities like Shenzhen, Qingdao, Xiamen and exported to countries such as Indonesia, and Azerbaijan.

According to Roy Zhu, Deputy Chairman and COO of Nationz Technologies, the number of patent applications for RCC already exceeded 800, with more than 400 patents already granted.

Furthermore the company has over 100 items filed for Patent Cooperation Treaty (PCT) international patents, which are protected by patent in countries such as America and Mexico.

The gold award is in recognition of the advancement RCC technology has brought and as a result Nationz are encouraged to grow faster, said Roy Zhu.

Chipscreen’s tumor inhibitor

 
 
Chipscreen is a leading integrated biotech company specializing in the discovery and development of novel small molecule pharmaceuticals. It aims to spearhead research and development of pharmaceuticals in China.

The patented drug receiving the award, chidamide is a histone deacetylase inhibitor (HDI) mainly used for preventing the recurrence and metastasis of tumors.

After being subject to multiple clinical trials for the treatment of various hematological and solid form cancers, its anticarconegenic effects are thought to be mediated through multiple mechanisms of action, including the inhibition of cell proliferation, induction of tumor specific antigens and antigen-specific T cell cytotoxicity.

According to Ning Zhiqiang, Excutive Vice President of Chipscreen, the patented medicine is the first original chemical drug developed in China to have been granted a patent for distribution in developed countries.

In 2006, Chipscreen were granted the patient and secured a 28 million USD contract with HUYA in America. In 2016, the patent was re-licensed in eight Southeast Asian countries including Japan, Korea, with resultant earnings of 280 million USD.

This increased revenue greatly increases Chipscreen’s competitiveness in research and development. The company’s next step is to spend more on R&D in order to invent highly marketable and innovative drugs, said Ning.

Author: Will

Editor: Simon

Related News